CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
0

Zebrafish Avatars Predict Tumor Response to Therapy

Cancer chemotherapeutic agents are developed and approved largely on the back of studies that demonstrate an average efficacy and safety across possibly thousands of patients. Even for emerging biomarker-driven treatments, there’s still no guarantee...

CHILD ARCHIVE CHILD ARCHIVE
0

Bugs and drugs: A work in progress

Gut microbes possibly influence not only the development of many human diseases, but also how these diseases respond to treatment. In tumor models, for example, gut microbes can modulate the efficacy and toxicity of...

CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
0

Cliques and Schisms of Cancer Genes

With a few exceptions, cancers typically carry more than one driver mutation, sometimes five, ten, or more, and these driver mutations do not necessarily assort randomly. In this issue of Cancer Cell, Mina et...

CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
0

Cell biology: Healthy skin rejects cancer

Live imaging shows that healthy skin cells surround and expel neighbours that have cancer-promoting mutations, revealing that tissues can recognize and eliminate mutant cells to prevent tumour initiation.

CHILD ARCHIVE CHILD ARCHIVE
0

A setback for immune checkpoint therapy?

Nivolumab, an immunotherapy drug, has shown unprecedented success at treating patients with certain types of advanced cancer. The U.S. Food and Drug Administration approvals for nivolumab, and other drugs like it, are for patients...

CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE CHILD ARCHIVE
CHILD ARCHIVE